RUNX1::RUNX1T1与CBFB::MYH11急性髓系白血病的临床特征和治疗决定因素不同。

IF 8.2 1区医学 Q1 HEMATOLOGY

Haematologica Pub Date : 2025-04-30 DOI:10.3324/haematol.2024.287293

Miao Yang,Wenting Wang,Guangji Zhang,Shaowei Qiu,Bingcheng Liu,Yingchang Mi,Ying Wang,Jianxiang Wang,Hui Wei

{"title":"RUNX1::RUNX1T1与CBFB::MYH11急性髓系白血病的临床特征和治疗决定因素不同。","authors":"Miao Yang,Wenting Wang,Guangji Zhang,Shaowei Qiu,Bingcheng Liu,Yingchang Mi,Ying Wang,Jianxiang Wang,Hui Wei","doi":"10.3324/haematol.2024.287293","DOIUrl":null,"url":null,"abstract":"Core binding factor acute myeloid leukemia (CBF-AML) includes RUNX1::RUNX1T1 and CBFB::MYH11 AML. To investigate whether they should be regarded as distinct entities and treated separately, we retrospectively analyzed 536 patients with CBF-AML aged 60 years or younger. For CBFB::MYH11 AML, no outcome differences were observed between standard-dose (SD) and intermediate-dose (ID) cytarabine induction, with 5-year overall survival (OS) and relapse-free survival (RFS) at 86.4% vs. 85.3% (P=0.99) and 74.1% vs. 68.4% (P=0.93), respectively. However, ID induction improved the outcomes of RUNX1::RUNX1T1 AML, with 5-year OS and RFS rates of 77.7% vs. 60.3% (P.","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":"31 1","pages":""},"PeriodicalIF":8.2000,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical characteristics and therapeutic determinants of RUNX1::RUNX1T1 differ from those of CBFB::MYH11 acute myeloid leukemia.\",\"authors\":\"Miao Yang,Wenting Wang,Guangji Zhang,Shaowei Qiu,Bingcheng Liu,Yingchang Mi,Ying Wang,Jianxiang Wang,Hui Wei\",\"doi\":\"10.3324/haematol.2024.287293\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Core binding factor acute myeloid leukemia (CBF-AML) includes RUNX1::RUNX1T1 and CBFB::MYH11 AML. To investigate whether they should be regarded as distinct entities and treated separately, we retrospectively analyzed 536 patients with CBF-AML aged 60 years or younger. For CBFB::MYH11 AML, no outcome differences were observed between standard-dose (SD) and intermediate-dose (ID) cytarabine induction, with 5-year overall survival (OS) and relapse-free survival (RFS) at 86.4% vs. 85.3% (P=0.99) and 74.1% vs. 68.4% (P=0.93), respectively. However, ID induction improved the outcomes of RUNX1::RUNX1T1 AML, with 5-year OS and RFS rates of 77.7% vs. 60.3% (P.\",\"PeriodicalId\":12964,\"journal\":{\"name\":\"Haematologica\",\"volume\":\"31 1\",\"pages\":\"\"},\"PeriodicalIF\":8.2000,\"publicationDate\":\"2025-04-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Haematologica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3324/haematol.2024.287293\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Haematologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3324/haematol.2024.287293","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

核心结合因子急性髓系白血病（CBF-AML）包括RUNX1::RUNX1T1和CBFB::MYH11 AML。为了研究它们是否应该被视为不同的实体并单独治疗，我们回顾性分析了536例60岁或以下的CBF-AML患者。对于CBFB::MYH11 AML，标准剂量（SD）和中剂量（ID）阿糖胞苷诱导之间没有观察到结果差异，5年总生存率（OS）和无复发生存率（RFS）分别为86.4%对85.3% （P=0.99）和74.1%对68.4% （P=0.93）。然而，ID诱导改善了RUNX1::RUNX1T1 AML的结果，5年OS和RFS率分别为77.7%和60.3% (P。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Clinical characteristics and therapeutic determinants of RUNX1::RUNX1T1 differ from those of CBFB::MYH11 acute myeloid leukemia.

Core binding factor acute myeloid leukemia (CBF-AML) includes RUNX1::RUNX1T1 and CBFB::MYH11 AML. To investigate whether they should be regarded as distinct entities and treated separately, we retrospectively analyzed 536 patients with CBF-AML aged 60 years or younger. For CBFB::MYH11 AML, no outcome differences were observed between standard-dose (SD) and intermediate-dose (ID) cytarabine induction, with 5-year overall survival (OS) and relapse-free survival (RFS) at 86.4% vs. 85.3% (P=0.99) and 74.1% vs. 68.4% (P=0.93), respectively. However, ID induction improved the outcomes of RUNX1::RUNX1T1 AML, with 5-year OS and RFS rates of 77.7% vs. 60.3% (P.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Haematologica 医学-血液学

CiteScore

14.10

自引率

2.00%

发文量

349

审稿时长

3-6 weeks

期刊介绍： Haematologica is a journal that publishes articles within the broad field of hematology. It reports on novel findings in basic, clinical, and translational research. Scope: The scope of the journal includes reporting novel research results that: Have a significant impact on understanding normal hematology or the development of hematological diseases. Are likely to bring important changes to the diagnosis or treatment of hematological diseases.